APREPITANT EVOLUGEN 125 mg, hard capsule and aprepitant evolugen 80 mg, hard capsule capsule
Active ingredients: Aprepitant
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Hard capsulecapsuleorale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- APREPITANT EVOLUGEN 125 mg, gélule et APREPITANT EVOLUGEN 80 mg, gélule
- Pharmaceutical form
- gélule et gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) aluminium OPA : polyamide orienté PVC de 1 gélule de 125 mg rose et blanche - plaquette(s) aluminium OPA : polyamide orienté PVC de 2 gélules de 80 mg blanches
- Marketing authorisation holder
- EVOLUPHARM
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 25 Jun 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65314130CIP73016895CIP133400930168950Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| APRÉPITANTgélule blanche | 80 mg · une gélule de 80 mg | SA |
| APRÉPITANTgélule blanche et rose | 125 mg · une gélule de 125 mg | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.